New ISACA Certification Helps Students and Career Changers Build IT Knowledge and Hands-On Skills to Thrive in IT Jobs
16.3.2021 18:12:00 EET | Business Wire | Press release
Those seeking a strong foundation in IT knowledge and hands-on experience to set themselves apart as they seek technology jobs can now earn the new Information Technology Certified Associate (ITCA) certification from global IT professional association and learning organization ISACA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005796/en/
As the need for skilled technology professionals continues to grow, the IT field presents numerous promising career paths for young professionals, recent graduates and career-changers. ISACA’s new Information Technology Certified Associate (ITCA) credential – which includes certificates in Computing Fundamentals, Networks and Infrastructure Fundamentals, Cybersecurity Fundamentals, Data Science Fundamentals and Software Development Fundamentals – prepares aspiring professionals for entry into an array of IT fields. (Graphic: Business Wire)
A dynamic addition to ISACA’s globally recognized credentials, ITCA offers students, recent graduates, those new to the IT profession or professionals seeking a career change with a flexible, hybrid format comprised of traditional knowledge-based learning and performance-based learning through live labs in a virtual environment. The certification can be achieved at one’s own pace by completing all the following modular certificates that focus on different domain areas in IT:
- Computing Fundamentals
- Networks and Infrastructure Fundamentals
- Cybersecurity Fundamentals
- Software Development Fundamentals
- Data Science Fundamentals
“A key part of ISACA’s commitment to providing tools for lifelong learning is supporting professionals at every stage of their career journey, including in that critical period at the very beginning—whether they are new graduates or professionals seeking to make a career change to IT,” says David Samuelson, ISACA CEO. “We are proud to be able to serve this new generation of IT professionals and thought leaders, including those transitioning their careers due to the pandemic, by helping them differentiate and elevate themselves as they enter the job market and start their careers.”
With ITCA, young professionals, students or recent graduates with degrees in IT or computer science, and those seeking a job change can prepare themselves for in-demand jobs like computer systems administrator, technical support specialist, database administrator, systems engineer, applications developer, front-end web developer, and quality assurance analyst. The certification can also serve more experienced audit, security or governance professionals looking to enhance their understanding of foundational IT concepts.
“Working within the IT industry presents so many amazing opportunities for recent graduates, young professionals and career-changers,” says Daisy Jardine-Viner, recruitment specialist, NDK Infosec. “It’s a constantly evolving and in-demand hiring environment that offers the chance to work at the forefront of technology.”
The ITCA program offers study guides, self-paced training courses, performance-based labs, and exams for each certificate, available at discounted rates to ISACA members. Once all five exams are completed, the candidate can apply to become ITCA certified.
For more information about ITCA, visit www.isaca.org/credentialing/itca. Learn more about ISACA’s other credentials at www.isaca.org/credentialing.
About ISACA
For more than 50 years, ISACA® (www.isaca.org) has been equipping individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of its more than 150,000 members to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005796/en/
Contact information
Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
